INTRODUCTION {#s1}
============

Approximately 337,860 cases of renal cell carcinoma (RCC) are diagnosed annually, and nearly 143,406 patients die from this cancer each year worldwide \[[@R1]\]. RCC is the third most common genitourinary malignancy. Moreover, both the incidence and mortality rates of RCC have steadily increased over the past several years \[[@R2]\]. The etiology of RCC is complex and multifactorial, and it involves multiple environmental and genetic factors \[[@R3],[@R4]\]. Although an increasing number of studies have been performed on the etiology of RCC, the real causes of this cancer remain unclear. Previous studies have shown that many environmental factors such as cigarette smoking, alcohol drinking, occupational exposure to chemicals, hypertension and low frequencies of physical activity increase the risk of RCC \[[@R5]--[@R7]\]. Although many people are exposed to these risk factors during their lifetime, only a few people develop RCC. This finding suggests that genetic susceptibility plays a critical role in the etiology of this disease \[[@R8], [@R9]\].

Vascular endothelial growth factor (VEGF) is an important pro-angiogenic growth factor, and it is one of the most potent endothelial cell mitogens \[[@R10], [@R11]\]. VEGF plays a critical role in regulating the egress of the plasma proteins and cells that directly and indirectly stimulate angiogenesis \[[@R12]\]. Some research has indicated that the expression of VEGF affects tumor growth and metastasis, whereas the inhibition of *VEGF* signaling suppresses both tumor-induced angiogenesis and tumor growth \[[@R13]\]. The *VEGF* gene is located at chromosome 6p21.3 and consists of 8 exons. At least 30 single nucleotide polymorphisms (SNPs) exist in this gene \[[@R14]\] and some experimental studies have shown that certain SNPs can affect gene expression and change gene function \[[@R15]\].

Recently, numerous studies have been performed to evaluate the association between *VEGF* polymorphisms and RCC risk in diverse populations; however, the results of these studies conflict. To examine the association between *VEGF* polymorphisms and RCC risk, we performed a meta-analysis of all eligible published data up to June 5, 2016.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

We performed a literature search, and 286 potentially relevant publications were identified. After screening the title and abstract of each study, 277 studies were excluded because they did not involve both *VEGF* polymorphisms and RCC risk. After the subsequent data extraction, one study was excluded because it lacked controls \[[@R16]\]. Finally, we obtained 8 relevant articles \[[@R17]--[@R24]\] that examined the association between *VEGF* polymorphisms and RCC risk (Figure [1](#F1){ref-type="fig"}); the data extracted from the articles are summarized in Table [1](#T1){ref-type="table"} . All of the included studies were evaluated using the Newcastle-Ottawa Scale (NOS) and were of high quality (Table [2](#T2){ref-type="table"}). Of the 8 studies, 6 focused on the +936C/T polymorphism (rs3025039), 5 discussed −2578C/A (rs699947), 3 discussed +1612G/A (rs10434), -460T/C (rs833061) and −634G/C (rs2010963), and 2 studies examined both -405G/C (rs2010963) and -1154G/A (rs1570360). All of the included articles (excluding Shen et al.\[[@R20]\] and Lu et al. \[[@R21]\]) were case control studies, and their genotypic distributions across the controls followed Hardy-Weinberg Equilibrium (HWE).

###### Characteristics of eligible studies in the meta-analysis of *VEGF* polymorphisms and RCC risk

  Author                     Year   Quality scores   Ethnicity   Design   Cases total       CC       CT       TT       Controls total       CC       CT       TT       *P* HWE
  -------------------------- ------ ---------------- ----------- -------- ----------------- -------- -------- -------- -------------------- -------- -------- -------- ---------
  **+936C/T (rs3025039)**                                                                                                                                              
   Abe A\[[@R17]\]           2002   5                Asian       HB       145               97       41       7        145                  90       52       3        0.146
   Bruyère F\[[@R18]\]       2010   5                Caucasian   PB       47                29       17       1        196                  141      53       2        0.218
   Sáenz-López P\[[@R19]\]   2013   6                Caucasian   PB       215               156      57       2        280                  200      73       7        0.912
   Shen BL\[[@R20]\]         2015   5                Asian       HB       360               224      81       55       359                  240      73       46       0.000
   Lu GJ\[[@R21]\]           2015   5                Asian       HB       412               262      91       59       825                  554      166      105      0.000
   Xian W\[[@R22]\]          2015   5                Asian       HB       266               70       127      69       532                  196      236      100      0.056
  **−2578C/A (rs699947)**                                                 **Cases total**   **CC**   **CA**   **AA**   **Controls total**   **CC**   **CA**   **AA**   
   Ajaz S\[[@R23]\]          2011   5                Asian       NA       143               30       81       32       106                  44       41       21       0.053
   Sáenz-López P\[[@R19]\]   2013   6                Caucasian   PB       216               54       114      48       272                  77       142      53       0.388
   Shen BL\[[@R20]\]         2015   5                Asian       HB       360               150      149      61       360                  178      141      41       0.111
   Lu GJ\[[@R21]\]           2015   5                Asian       HB       412               171      174      67       824                  397      332      95       0.047
   Xian W\[[@R22]\]          2015   5                Asian       HB       266               99       119      48       532                  243      225      64       0.287
  **+1612G/A (rs10434)**                                                  **Cases total**   **GG**   **GA**   **AA**   **Controls total**   **GG**   **GA**   **AA**   
   Abe A\[[@R17]\]           2002   5                Asian       HB       145               113      31       1        145                  109      33       3        0.788
   Shen BL\[[@R18]\]         2015   5                Asian       HB       361               152      170      39       360                  166      164      30       0.234
   Lu GJ\[[@R21]\]           2015   5                Asian       HB       412               172      191      49       825                  365      375      85       0.431
  **-460T/C (rs833061)**                                                  **Cases total**   **TT**   **TC**   **CC**   **Controls total**   **TT**   **TC**   **CC**   
   Bruyère F\[[@R18]\]       2010   5                Caucasian   PB       49                19       29       1        202                  47       109      46       0.260
   Sáenz-López P\[[@R19]\]   2013   6                Caucasian   PB       216               56       111      49       273                  77       138      58       0.793
   Lu GJ\[[@R21]\]           2015   5                Asian       HB       412               228      93       91       824                  513      168      143      0.000
  **−634G/C (rs2010963)**                                                 **Cases total**   **GG**   **GC**   **CC**   **Controls total**   **GG**   **C**    **CC**   
   Shen BL\[[@R20]\]         2015   5                Asian       HB       360               121      170      69       360                  134      163      63       0.273
   Lu GJ\[[@R21]\]           2015   5                Asian       HB       412               139      194      79       824                  299      377      148      0.127
   Xian W\[[@R22]\]          2015   5                Asian       HB       266               30       132      104      532                  49       256      227      0.053
  **-405G/C (rs2010963)**                                                 **Cases total**   **GG**   **GC**   **CC**   **Controls total**   **GG**   **GC**   **CC**   
   Bruyère F\[[@R18]\]       2010   5                Caucasian   PB       48                15       25       8        198                  86       92       20       0.522
   Sáenz-López P\[[@R19]\]   2013   6                Caucasian   PB       214               101      93       20       279                  129      118      32       0.528
  **-1154G/A (rs1570360)**                                                **Cases total**   **GG**   **GA**   **AA**   **Controls total**   **GG**   **GA**   **AA**   
   Ricketts C\[[@R24]\]      2009   6                Caucasian   PB       324               134      143      47       314                  146      130      38       0.281
   Bruyère F\[[@R18]\]       2010   5                Caucasian   PB       49                27       17       5        202                  94       83       25       0.322

HB, hospital-based controls; HWE, Hardy-Weinberg equilibrium.

![Flow diagram of the study selection](oncotarget-08-8447-g001){#F1}

###### Quality assessment based on the Newcastle-Ottawa Scale of studies included in this meta-analysis[^a^](#tfn_001){ref-type="table-fn"}

  Author                    Year   Adequate definition of case   Representativeness of cases   Selection of control   Definition of control   Control for important factor or additional factor[^b^](#tfn_002){ref-type="table-fn"}   Exposure assessment   Same method of ascertainment for cases and controls   Nonresponse rate   Total quality scores
  ------------------------- ------ ----------------------------- ----------------------------- ---------------------- ----------------------- --------------------------------------------------------------------------------------- --------------------- ----------------------------------------------------- ------------------ ----------------------
  Abe A\[[@R17]\]           2002   ★                             ★                                                    ★                       ★                                                                                                             ★                                                                        5
  Bruyère F\[[@R18]\]       2010   ★                             ★                             ★                      ★                                                                                                                                     ★                                                                        5
  Sáenz-López P\[[@R19]\]   2013   ★                             ★                             ★                      ★                       ★                                                                                                             ★                                                                        6
  Shen BL\[[@R20]\]         2015   ★                             ★                                                    ★                       ★                                                                                                             ★                                                                        5
  Lu GJ\[[@R21]\]           2015   ★                             ★                                                    ★                       ★                                                                                                             ★                                                                        5
  Xian W\[[@R22]\]          2015   ★                             ★                                                    ★                       ★                                                                                                             ★                                                                        5
  Ajaz S\[[@R23]\]          2011   ★                             ★                                                    ★                       ★                                                                                                             ★                                                                        5
  Ricketts C\[[@R24]\]      2009   ★                             ★                             ★                      ★                       ★                                                                                                             ★                                                                        6

A study can be awarded a maximum of one star for each numbered item except for the item Control for important factor or additional factor.

A maximum of two stars can be awarded for Control for important factor or additional factor.

+936C/T (rs3025039) {#s2_2}
-------------------

Six studies \[[@R17]--[@R22]\] including 1,445 cases and 2,337 controls examining the +936C/T (rs3025039) polymorphism were pooled. Overall, significant increased cancer risks were observed in most genetic models and alleles (TT vs. CC: odds ratio \[OR\]=1.38, 95% confidence intervals \[CIs\]=1.11-1.72, *P*=0.004, *I^2^*=25.3, Figure [2A](#F2){ref-type="fig"}; TT vs. CT+CC: OR=1.28, 95% CIs=1.04-1.57, *P*=0.019, *I^2^*=0.0, Figure [2B](#F2){ref-type="fig"}; TT+CT vs. CC: OR=1.21, 95% CIs=1.05-1.39, *P*=0.010, *I^2^*=38.7, Figure [2C](#F2){ref-type="fig"}; T vs. C: OR=1.20, 95% CIs=1.07-1.34, *P*=0.001, *I^2^*=32.0, Figure [2E](#F2){ref-type="fig"}) except CT vs. CC (OR=1.17, 95% CIs=1.00-1.37, *P*=0.056, *I^2^*=25.3, Figure [2D](#F2){ref-type="fig"}).

![Forest plots of the +936C/T (rs3025039) polymorphism and RCC risk\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which was the inverse of the variance). The diamonds represent the pooled ORs and 95% CIs.](oncotarget-08-8447-g002){#F2}

−2578C/A (rs699947) {#s2_3}
-------------------

Five articles \[[@R19]--[@R25]\] including 1,397 cases and 2,094 controls examined the relationship between the −2578C/A (rs699947) polymorphism and RCC risk. Remarkably, significant associations were found in all genetic models (AA vs. CC: OR=1.69, 95% CIs=1.37-2.07, *P*=0.000, *I^2^*=0.0, Figure [3A](#F3){ref-type="fig"}; AA vs. CA+CC: OR=1.43, 95% CIs=1.19-1.73, *P*=0.000, *I^2^*=0.0, Figure [3B](#F3){ref-type="fig"}; AA+CA vs. CC: OR=1.39, 95% CIs=1.21-1.61, *P*=0.000, *I^2^*=34.8, Figure [3C](#F3){ref-type="fig"}; CA vs. CC: OR=1.31, 95% CIs=1.12-1.52, *P*=0.001, *I^2^*=47.1, Figure [3D](#F3){ref-type="fig"}), and also the A vs. C allele (OR=1.31, 95% CIs=1.19-1.45, *P*=0.000, *I^2^*=0.0, Figure [3E](#F3){ref-type="fig"}).

![Forest plots of the −2578C/A (rs699947) polymorphism and RCC risk\
The squares and horizontal lines correspond to the study-specific ORs and 95% CIs. The areas of the squares reflect the study-specific weights (which were the inverse of the variance). Diamonds represent the pooled ORs and 95% CIs.](oncotarget-08-8447-g003){#F3}

+1612G/A (rs10434), -460T/C (rs833061) and −634G/C (rs2010963) {#s2_4}
--------------------------------------------------------------

Three studies discussed the +1612G/A (rs10434) \[[@R17], [@R20], [@R21]\], -460T/C (rs833061) \[[@R18], [@R19], [@R21]\] and −634G/C (rs2010963) \[[@R20]--[@R22]\] polymorphisms. The numbers of participants in these studies were 918, 677 and 1,038 cases and 1,330, 1,299 and 1,716 controls, respectively. Unfortunately, no significant associations were found between RCC risks and in any genetic model or allele of these three polymorphisms.

-405G/C (rs2010963) and -1154G/A (rs1570360) {#s2_5}
--------------------------------------------

We also investigated the -405G/C (rs2010963) \[[@R18], [@R19]\] and -1154G/A (rs1570360) \[[@R18], [@R24]\] polymorphisms, both of which were examined in two studies including 262 and 373 cases and 477 and 516 controls, respectively. However, we did not identify any association between RCC risk and either the -405G/C (rs2010963) or -1154G/A (rs1570360) polymorphism.

Sensitivity analyses {#s2_6}
--------------------

Hardy-Weinberg disequilibrium was observed in two studies (Shen et al.\[[@R20]\] and Lu et al. \[[@R21]\]). For +936C/T (rs3025039) polymorphism, our sensitivity analyses results indicated that exclusion of the aforementioned studies did not change the results for all the genetic models and allele (data not shown). In addition, for −2578C/A (rs699947) polymorphism, the sensitivity analyses results for all the genetic models and allele did not change either when excluding the study of Lu et al. \[[@R21]\] (data not shown).

Publication bias {#s2_7}
----------------

Except for the -405G/C (rs2010963) and -1154G/A (rs1570360) polymorphisms, we used both funnel plots and Egger\'s test to assess the publication bias of each genetic model and allele. Our results did not show a publication bias for most of the genetic models and alleles ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}-[2](#SD1){ref-type="supplementary-material"} showed the funnel plots of +936C/T and −2578C/A polymorphisms, respectively), except regarding CC vs. CT+TT of the -460T/C (rs833061) polymorphism (*P*=0.038).

DISCUSSION {#s3}
==========

VEGF, a growth factor that regulates angiogenesis and is involved in promoting endothelial cell proliferation \[[@R25]\]. VEGF protein likely plays an important role in the development and progression of cancer. Researchers have found that the expression of *VEGF* is significantly related to tumor stage, tumor size, and nuclear grade in patients with clear cell RCC \[[@R26]\]. In addition, the overexpression of *VEGF* has been detected in the vast majority of RCC tissues \[[@R27]\]. Currently, *VEGF* inhibition is a therapy for RCC \[[@R28]\]. However, the *VEGF* gene is highly polymorphic \[[@R29]\] and several functional SNPs in the *VEGF* gene alter the expression of the VEGF protein, thereby affecting tumor growth and progression. Recent studies have investigated the association between SNPs in the *VEGF* gene and the risk of RCC. However, these results are controversial. Thus, we conducted this meta-analysis to discuss the relationship between *VEGF* polymorphisms and RCC risk.

Zhang et al. \[[@R30]\] previously performed a meta-analysis that observed the association between *VEGF* polymorphisms and RCC risk. However, the author only reviewed 5 studies. In contrast, our meta-analysis included 8 relevant published studies. Moreover, our meta-analysis included many more cases and controls than the prior meta-analysis. In addition, we evaluated the quality of studies using the NOS. All of the included studies met high-quality standards, whereas the prior meta-analysis did not conduct any quality assessment. Thus, our meta-analysis is a more convincing and detailed evaluation compared with the prior study. Overall, we found that significant associations exist between *VEGF* polymorphisms and RCC risk (all of our results are summarized in Table [3](#T3){ref-type="table"}). Specifically, most genetic models and alleles found high risks of RCC regarding the +936C/T (rs3025039) polymorphism. To the best of our knowledge, our study is the first meta-analysis to report that the +936C/T (rs3025039) polymorphism of *VEGF* can increase the risk of RCC. The +936C/T (rs3025039) polymorphism is located in the 3′-UTR and likely associated with obviously increased serum VEGF levels \[[@R31]\], which are related to tumor stage, tumor size, and nuclear grade. Interestingly, according to the results of Krippl P \[[@R32]\], the carriers of a +936 T allele had significant decreased risks of breast cancer and lower serum VEGF levels, which is opposite with our results. The reason of this discrepancy may be the tumor heterogeneity. Tumor heterogeneity is complex in many levels, including interdisease, intertumor, intratumor and tumor-microenvironment heterogeneity, etc. \[[@R33]\]. Furthermore, significant RCC risks were found in all genetic models and alleles of the -2578C/A (rs699947) polymorphism, whereas the prior meta-analysis only found increased RCC risks for the AA vs. CC genetic model and the A vs. C allele. Currently, several studies have reported that the -2578C/A (rs699947) polymorphism in the promoter region plays an influential role regarding plasma VEGF levels \[[@R34], [@R35]\]. However, no significant associations were found between RCC risk and the +1612G/A (rs10434), -460T/C (rs833061), −634G/C (rs2010963), -405G/C (rs2010963) or -1154G/A (rs1570360) polymorphisms. All of the characteristics and results of the present study were compared with the former meta-analysis and summarized in Table [4](#T4){ref-type="table"}.

###### Summary of meta-analysis of *VEGF* polymorphisms and RCC risk

  Polymorphism   No. of studies   No. of cases   No. of controls   Contrast       OR (95% CI)       Statistical method   I^2^%   *P*-value
  -------------- ---------------- -------------- ----------------- -------------- ----------------- -------------------- ------- -----------
  +936C/T        6                1,445          2,337             TT vs. CC      1.38(1.11-1.72)   Fixed                25.3    0.004
  (rs3025039)                                                      TT vs. CT+CC   1.28(1.04-1.57)   Fixed                0.0     0.019
                                                                   TT+CT vs. CC   1.21(1.05-1.39)   Fixed                38.7    0.010
                                                                   CT vs. CC      1.17(1.00-1.37)   Fixed                25.3    0.056
                                                                   T vs. C        1.20(1.07-1.34)   Fixed                32.0    0.001
  −2578C/A       5                1,397          2,094             AA vs. CC      1.69(1.37-2.07)   Fixed                0.0     0.000
  (rs699947)                                                       AA vs. CA+CC   1.43(1.19-1.73)   Fixed                0.0     0.000
                                                                   AA+CA vs. CC   1.39(1.21-1.61)   Fixed                34.8    0.000
                                                                   CA vs. CC      1.31(1.12-1.52)   Fixed                47.1    0.001
                                                                   A vs. C        1.31(1.19-1.45)   Fixed                0.0     0.000
  +1612G/A       3                918            1,330             AA vs. GG      1.25(0.92-1.71)   Fixed                0.0     0.159
  (rs10434)                                                        AA vs. GA+GG   1.20(0.89-1.61)   Fixed                0.0     0.234
                                                                   AA+GA vs. GG   1.10(0.92-1.31)   Fixed                0.0     0.280
                                                                   GA vs. GG      1.08(0.90-1.30)   Fixed                0.0     0.423
                                                                   A vs. G        1.10(0.96-1.25)   Fixed                0.0     0.178
  −460T/C        3                677            1,299             CC vs. TT      0.88(0.38-2.01)   Random               80.6    0.758
  (rs833061)                                                       CC vs. TC+TT   0.93(0.47-1.84)   Random               77.9    0.830
                                                                   CC+TC vs. TT   0.98(0.61-1.58)   Random               75.5    0.928
                                                                   TC vs. TT      1.12(0.89-1.41)   Fixed                31.0    0.343
                                                                   C vs. T        0.92(0.58-1.46)   Random               87.9    0.720
  −634G/C        3                1,038          1,716             CC vs. GG      1.07(0.84-1.35)   Fixed                16.4    0.581
  (rs2010963)                                                      CC vs. GC+GG   1.00(0.83-1.20)   Fixed                0.0     1.000
                                                                   CC+GC vs. GG   1.09(0.91-1.30)   Fixed                0.0     0.370
                                                                   GC vs. GG      1.08(0.89-1.31)   Fixed                0.0     0.429
                                                                   C vs. G        1.03(0.92-1.16)   Fixed                27.7    0.571
  −405G/C        2                262            477               CC vs. GG      1.26(0.45-3.51)   Random               68.4    0.661
  (rs2010963)                                                      CC vs. GC+GG   1.11(0.51-2.41)   Random               54.5    0.796
                                                                   CC+GC vs. GG   1.18(0.70-2.01)   Random               52.5    0.536
                                                                   GC vs. GG      1.11(0.80-1.55)   Fixed                13.0    0.532
                                                                   C vs. G        1.14(0.72-1.79)   Random               67.0    0.584
  −1154G/A       2                373            516               AA vs. GG      1.19(0.77-1.84)   Fixed                19.9    0.435
  (rs1570360)                                                      AA vs. GA+GG   1.14(0.76-1.73)   Fixed                0.0     0.528
                                                                   AA+GA vs. GG   1.00(0.59-1.69)   Random               58.1    0.994
                                                                   GA vs. GG      1.08(0.80-1.46)   Fixed                45.3    0.611
                                                                   A vs. G        1.01(0.68-1.51)   Random               57.1    0.948

###### Characteristics and results of the present study compared with the previous meta-analysis

  Polymorphism   Contrast       No. of studies   No. of cases   No. of controls   Overall results                      
  -------------- -------------- ---------------- -------------- ----------------- ----------------- ----- ------- ---- ----
  +936C/T        TT vs. CC      3                6              407               1,445             621   2,337   --   \+
  (rs3025039)    TT vs. CT+CC                                                                                     --   \+
                 TT+CT vs. CC                                                                                     --   \+
                 CT vs. CC                                                                                        --   --
                 T vs. C                                                                                          --   \+
  −2578C/A       AA vs. CC      2                5              359               1,397             378   2,094   \+   \+
  (rs699947)     AA vs. CA+CC                                                                                     --   \+
                 AA+CA vs. CC                                                                                     --   \+
                 CA vs. CC                                                                                        --   \+
                 A vs. C                                                                                          \+   \+
  +1612G/A       AA vs. GG      NA               3              NA                918               NA    1,330   NA   --
  (rs10434)      AA vs. GA+GG                                                                                     NA   --
                 AA+GA vs. GG                                                                                     NA   --
                 GA vs. GG                                                                                        NA   --
                 A vs. G                                                                                          NA   --
  −460T/C        CC vs. TT      2                3              265               677               475   1,299   --   --
  (rs833061)     CC vs. TC+TT                                                                                     --   --
                 CC+TC vs. TT                                                                                     --   --
                 TC vs. TT                                                                                        --   --
                 C vs. T                                                                                          --   --
  −634G/C        CC vs. GG      NA               3              NA                1,038             NA    1,716   NA   --
  (rs2010963)    CC vs. GC+GG                                                                                     NA   --
                 CC+GC vs. GG                                                                                     NA   --
                 GC vs. GG                                                                                        NA   --
                 C vs. G                                                                                          NA   --
  −405G/C        CC vs. GG      2                2              262               262               477   477     --   --
  (rs2010963)    CC vs. GC+GG                                                                                     --   --
                 CC+GC vs. GG                                                                                     --   --
                 GC vs. GG                                                                                        --   --
                 C vs. G                                                                                          --   --
  −1154G/A       AA vs. GG      2                2              373               373               516   516     --   --
  (rs1570360)    AA vs. GA+GG                                                                                     --   --
                 AA+GA vs. GG                                                                                     --   --
                 GA vs. GG                                                                                        --   --
                 A vs. G                                                                                          --   --

Certain limitations of this meta-analysis should be acknowledged. First, because our study only considered published articles, a publication bias might exist. However, the publication bias was only found for the CC vs. CT+TT of -460T/C (rs833061) polymorphism. The statistical results of the funnel plot and Egger\'s test support this finding. Second, the heterogeneities among certain genetic models and alleles were significant. The reasons underlying these heterogeneities included the source of the controls, the study design and differences in genetic backgrounds. Third, the control sample of two articles were in Hardy-Weinberg disequilibrium, however, all the results of +936C/T (rs3025039) and -2578C/A (rs699947) polymorphisms did not change significantly after sensitivity analyses. Fourth, as the most of the cases of +936C/T and -2578C/A polymorphisms were from Asians, so our results of these two SNPs may not represent Caucasians. Finally, because of the use of unadjusted data, potential confounds such as age, sex and residence might also have affected the effect estimates. Thus, a more precise and large scale evaluation based on adjusted data is needed.

In summary, our meta-analysis suggests that the +936C/T (rs3025039) and -2578C/A (rs699947) polymorphisms of *VEGF* are associated with increased risks for RCC. However, no significant RCC risks were obtained regarding the +1612G/A (rs10434), -460T/C (rs833061), -634G/C (rs2010963), -405G/C (rs2010963) or -1154G/A (rs1570360) polymorphisms. To the best of our knowledge, this meta-analysis is the first to report that the +936C/T (rs3025039) polymorphism can increase the risk of RCC. Larger and more rigorous analytical studies are required to confirm our results and evaluate the gene-environment interactions with regard to RCC risk.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and selection criteria {#s4_1}
--------------------------------------

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we performed an electronic systematic search of PubMed, the Cochrane Library database, EMBASE, Google Scholar and the China National Knowledge Infrastructure (CNKI) without any restriction on language up to June 5, 2016. The combinations of keywords used were "renal cancer" or "renal carcinoma"; "polymorphism" or "variant"; and "vascular endothelial growth factor" or "VEGF." In addition, the reference lists of the papers retrieved and recent reviews were also examined. We included all studies that (1) evaluated the association between *VEGF* polymorphisms and the risk of RCC in humans; (2) used a case control design; (3) confirmed RCC using the accepted diagnostic criteria; (4) reported sufficient published data, including ORs and their 95% CIs, or the number of events for the purposes of calculation. The exclusion criteria were (1) a lack of sufficient data to calculate ORs with corresponding 95% CIs; and (2) overlapping cases or controls. Only the most recent or the largest research study was included in the case of overlap.

Data extraction {#s4_2}
---------------

Two investigators (GMC and DWJ) extracted the raw data independently based on the inclusion and exclusion criteria. The following information was extracted from all of the enrolled studies (see Table [1](#T1){ref-type="table"}): the surname of the first author, date of publication, participant ethnicity, quality scores, sources of controls, number of cases and controls and the HWE *P-*value. All disagreements were resolved via discussion.

Quality assessment {#s4_3}
------------------

Two authors (GMC and SZR) assessed the study quality using the NOS \[[@R36]\] which evaluates methodological quality using a star rating system. Nine stars was defined as a full score; 5 to 9 stars was considered as being of high methodological quality; and 0 to 4 stars was considered as being of poor quality \[[@R37]\]. The quality of all the included studies is listed in Table [2](#T2){ref-type="table"}. For conflicting NOS scores, an agreement was reached via a comprehensive reassessment, and only high-quality studies were included in our meta-analysis.

Statistical analysis {#s4_4}
--------------------

The relationship between *VEGF* polymorphisms and the risk of RCC was evaluated via pooled ORs with 95% CIs. The significance of the pooled ORs was tested using the *Z*-test, and a (two-tailed) *P*-value of \<0.05 was regarded as significant. The HWE was calculated in the control groups using the chi-square test, and *P*\<0.05 signified a departure from HWE. Between-study heterogeneity was calculated using the *I^2^* test. If the heterogeneity was significant (*I^2^*\>50%) \[[@R38]\], then a random-effects model was used (the DerSimonian and Laird method) \[[@R39]\]; otherwise, the fixed-effect model (the Mantel-Haenszel method) \[[@R40]\] was applied. To assess the stability of the results, sensitivity analyses were conducted to evaluate the impact of the studies, especially which not in HWE. Because publication bias is always a concern for meta-analyses, funnel plots and Egger\'s test were both used to examine publication bias (*P*\<0.05 was considered as significant publication bias) \[[@R41]\]. All statistical analyses were performed using STATA statistical software (Version 12.0; Stata Corporation, College Station, TX, USA).
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